Treatment of iodine negative, thyroglobulin positive, thyroid cancer patients: Do we miss the target when we shoot in the dark?

Nuclear Medicine Communications

Volumn 24, Issue 7, 2003, Pages 739-741

  Kabasakal, L ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN;

BLOOD; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HUMAN; METHODOLOGY; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; SCINTISCANNING; THYROID TUMOR;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IODINE RADIOISOTOPES; PATIENT SELECTION; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 0242492324     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200307000-00001     Document Type: Editorial

References (15)

1. Yüksel D, Argon M, Atasever T, et al. Guideline for I-131 ablation and treatment of well differentiated thyroid cancer. Turc J Nucl Med 2001;: S23-S28.
2. Atay-Rosenthal S. Controversies of treatment of well-differentiated thyroid carcinoma and factors influencing prognosis. In: Freeman LM, editor. Nuclear Medicine Annual. Philadelphia: Williams and Wilkins; 1999. 3303-3334.
3. Schulumberger M, Arcangioli O, Pierkarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988;: 1790-1794.
4. Mezzafferri EL. Treating high thyroglobulin with radioiodine: A magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995;: 1485-1487.
5. Waxman A, Ramanna L, Chapman N, et al. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation. J Nucl Med 1981;: 861-865.
6. Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;: 629-634.
7. Paccini F, Lippi F, Formica N, et al. Thrapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;: 1888-1891.
8. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;: 1488-1492.
9. De Keizer B, Koppeschaar HPF, Zelissen PMJ, et al. Efficacy of high therapeutic doses of ioidine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001;: 198-202.
10. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole body scan: Comparison of patients treated with high I-131 activities versus untreated patients. J Clin Endocrinol Metab 2001;: 4092-4097.
11. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 2000;: 107-114.
12. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tgpositive, diagnostic whole body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 2002;: 1521-1526.
13. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of 18-F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results after therapy. J Nucl Med 2001;: 1464-1469.
14. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 2001;: 77-78.
15. Cailleux AF, Baudin E, Travagli JP, Ricard M, Shulumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;: 175-178.